{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Complete response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"157"}]}],"title":"Partial response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"49"}]}],"title":"Stable disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"}]}],"title":"Progressive disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"}]}],"title":"Indeterminate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"227"},{"groupId":"OG001","value":"225"}],"units":"Participants"}],"description":"BOR for CR/PR:\\>=1 objective status (OBS) of CR/PR documented before PD; SD:\\>=1 OBS of stable documented \\>=8 weeks (wks) post treatment \\& before PD, not qualifying as CR/PR; PD:OBS of PD within 12 wks treatment, not qualifying as CR/PR/SD; indeterminate:PD not documented within 12 wks post treatment \\& no other response category applies. RECIST v1.1, CR:disappearance of all target lesions (TLs), non TLs;any pathological lymph nodes (LN) must reduce in short axis to \\<10 mm; normalization of tumour marker level, for non TL all LN must be non-pathological in size (\\<10 mm short axis); PR:\\>=30% decrease in sum of diameters of TLs, referring baseline sum diameters. SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referring smallest sum diameters on study. PD:\\>=20% increase in sum of diameters of TLs, referring smallest sum on study, sum must be an absolute increase of \\>=5 mm, appearance of \\>=1 new lesions;unequivocal progression of existing non TLs.","groups":[{"description":"Participants received 45 mg of dacomitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG000","title":"Dacomitinib"},{"description":"Participants received 250 mg of gefitinib tablets orally once daily in each treatment cycle of 28 days, up to a maximum of 48 months until disease progression, intolerable toxicities, withdrawal, death, or investigator decision dictated by protocol compliance, whichever occurred first.","id":"OG001","title":"Gefitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ITT Population included all randomized participants, with study treatment assignment designated according to initial randomization, regardless of whether participants received study treatment or a different treatment from that to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression (up to 48 months)","title":"Number of Participants With Best Overall Response (BOR) Based on Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Participants"}